Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report), retaining the price target of $10.00.
Ram Selvaraju has given his Buy rating due to a combination of factors including the completion of the New Drug Application (NDA) submission for Anaphylm™, a promising non-device-based epinephrine product candidate by Aquestive Therapeutics. The product has shown clinical results comparable to existing autoinjectors like EpiPen, particularly in treating severe allergic reactions such as anaphylaxis. The successful completion of adult clinical trials and positive feedback from the FDA in pre-NDA meetings further bolster confidence in the product’s potential.
Additionally, the positive outcomes from pediatric studies, which demonstrated a consistent pharmacokinetic profile and no serious adverse events, enhance the prospects for Anaphylm’s approval. Aquestive’s strategic preparations for a potential advisory committee meeting and the anticipated FDA acceptance of the NDA submission in the second quarter of 2025 are also pivotal. These developments, along with plans for a U.S. launch in the first quarter of 2026, if approved, underpin Selvaraju’s optimistic outlook and the reiteration of a Buy rating with a 12-month price target of $10.
Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Axsome Therapeutics, and Emergent Biosolutions. According to TipRanks, Selvaraju has an average return of -0.2% and a 34.69% success rate on recommended stocks.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $9.00 price target.